JP2022551256A5 - - Google Patents

Info

Publication number
JP2022551256A5
JP2022551256A5 JP2022520238A JP2022520238A JP2022551256A5 JP 2022551256 A5 JP2022551256 A5 JP 2022551256A5 JP 2022520238 A JP2022520238 A JP 2022520238A JP 2022520238 A JP2022520238 A JP 2022520238A JP 2022551256 A5 JP2022551256 A5 JP 2022551256A5
Authority
JP
Japan
Prior art keywords
compound
substituted
alkyl
pharmaceutical composition
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551256A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/059101 external-priority patent/WO2021064570A1/en
Publication of JP2022551256A publication Critical patent/JP2022551256A/ja
Publication of JP2022551256A5 publication Critical patent/JP2022551256A5/ja
Pending legal-status Critical Current

Links

JP2022520238A 2019-10-01 2020-09-29 ヒト免疫不全ウイルスの複製阻害剤 Pending JP2022551256A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962908677P 2019-10-01 2019-10-01
US62/908,677 2019-10-01
US201962924781P 2019-10-23 2019-10-23
US62/924,781 2019-10-23
US202062967761P 2020-01-30 2020-01-30
US62/967,761 2020-01-30
PCT/IB2020/059101 WO2021064570A1 (en) 2019-10-01 2020-09-29 N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2022551256A JP2022551256A (ja) 2022-12-08
JP2022551256A5 true JP2022551256A5 (cg-RX-API-DMAC7.html) 2023-10-10

Family

ID=72811912

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520238A Pending JP2022551256A (ja) 2019-10-01 2020-09-29 ヒト免疫不全ウイルスの複製阻害剤

Country Status (5)

Country Link
US (1) US20220409619A1 (cg-RX-API-DMAC7.html)
EP (1) EP4038064B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022551256A (cg-RX-API-DMAC7.html)
ES (1) ES2974657T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021064570A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) * 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체

Similar Documents

Publication Publication Date Title
JP7641388B2 (ja) 一連のピペリジン置換安息香酸系化合物及びその使用
CN109803967B (zh) 二氢嘧啶类化合物及其制备方法和用途
CA3142069A1 (en) Aurora kinase inhibitor and use thereof
CN112771027A (zh) 溶血磷脂酸受体拮抗剂及其制备方法
WO2015118057A1 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2881322A1 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
JP2003535860A (ja) 新規なオキサゾリジノン誘導体及びその製造方法
CN102112453A (zh) 新的钾通道阻断剂及其用途
JP2023513419A (ja) オーロラa選択的阻害剤として有用な新規複素環式化合物
JP2023517043A5 (cg-RX-API-DMAC7.html)
TW201625581A (zh) 側氧雜環衍生物
KR20190129034A (ko) 금속효소 억제제 화합물
CA2938703A1 (en) Substituted thiazole or oxazole p2x7 receptor antagonists
EA031614B1 (ru) Трициклические атропоизомерные соединения
TW202102474A (zh) 吡咯化合物
JP2022551254A5 (cg-RX-API-DMAC7.html)
AU2004226207A1 (en) 4-substituted quinolein derivatives with antimicrobial activity
JP2024514251A (ja) 二環式化合物の製造方法及び抗菌剤としての使用
CN112236424A (zh) 经烷氧基取代的吡啶基衍生物
JP2008504351A (ja) 4−置換キノリン誘導体、その製造方法およびそのための中間体、ならびにこれを含む医薬組成物
CN112898316A (zh) 新型吡咯化合物
JP7168245B2 (ja) 三環式化合物
JP2022541772A (ja) インターロイキンの調節におけるプロドラッグ
EP3743419B1 (en) Novel compounds for the treatment of parasitic infections
CN110590839B (zh) 一种乐伐替尼衍生物及制备方法和用途